World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
55
Citations
11550
World Ranking
3800
National Ranking
157

David Ritchie publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where David Ritchie sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 377 publications — 78th percentile

78% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

David Ritchie D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where David Ritchie sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 55 D-Index — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 2013 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

David Ritchie is affiliated with the Peter MacCallum Cancer Centre in Australia and has extensively contributed to the fields of medicine, particularly focusing on hematology and oncology. With a publication record concentrated in hematology, oncology, genetics, pathology and forensic medicine, and immunology, their research covers a broad spectrum within medical sciences.

The main topics of David Ritchie's work include:

  • Hematopoietic Stem Cell Transplantation
  • Lymphoma Diagnosis and Treatment
  • Acute Myeloid Leukemia Research
  • Chronic Lymphocytic Leukemia Research
  • CAR-T Cell Therapy Research
  • Chronic Myeloid Leukemia Treatments
  • Acute Lymphoblastic Leukemia Research

Frequent publication venues for Ritchie's work include:

  • Blood
  • Internal Medicine Journal
  • Bone Marrow Transplantation
  • Leukemia & Lymphoma / Leukemia and Lymphoma
  • Transplantation and Cellular Therapy

Notable recent papers authored or co-authored by David Ritchie are:

  • Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance, 2020, The Medical Journal of Australia
  • Value and affordability of CAR T-cell therapy in the United States, 2020, Bone Marrow Transplantation
  • Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II), 2021, JAMA Oncology
  • T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy, 2021, Frontiers in Immunology
  • Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome, 2022, Blood

Collaborations have been an essential part of Ritchie's scientific activity, frequently co-authoring with:

  • Rachel Koldej
  • Ashish Bajel
  • Piers Blombery
  • Travis Perera
  • Constantine S. Tam

David Ritchie was recognized as a Fellow of the American Association for the Advancement of Science (AAAS) in 2013, acknowledging their contributions to scientific research and advancement.

Best Publications

  • Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

    H Quach;D Ritchie;D Ritchie;A K Stewart;P Neeson

  • The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions

    Christopher J Chan;Ludovic Martinet;Susan Gilfillan;Fernando Souza-Fonseca-Guimaraes

  • Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia.

    David S. Ritchie;Paul J. Neeson;Paul J. Neeson;Amit Khot;Stefan Peinert

  • Late Ebola virus relapse causing meningoencephalitis: a case report.

    Michael Jacobs;Alison Rodger;David J Bell;Sanjay Bhagani

  • Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity.

    A J Davenport;R S Cross;R S Cross;K A Watson;Y Liao

  • CD8+ T Cell-Dependent Elimination of Dendritic Cells In Vivo Limits the Induction of Antitumor Immunity

    Ian F. Hermans;David S. Ritchie;Jianping Yang;Joanna M. Roberts

  • Human blood MAIT cell subsets defined using MR1 tetramers.

    Nicholas A. Gherardin;Michael N.T. Souter;Hui Fern Koay;Kirstie M. Mangas

  • Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy

    Charlotte F. M. Hughes;Charlotte F. M. Hughes;Amit Khot;Christopher McCormack;Christopher McCormack;Stephen Lade

  • Autoimmunity associated with immunotherapy of cancer.

    Sally M. Amos;Connie P. M. Duong;Jennifer A. Westwood;David S. Ritchie

  • The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy

    Andy K. Hsu;Hang Quach;Hang Quach;Tsin Tai;H. Miles Prince;H. Miles Prince

  • Diversity of T Cells Restricted by the MHC Class I-Related Molecule MR1 Facilitates Differential Antigen Recognition

    Nicholas A. Gherardin;Nicholas A. Gherardin;Andrew N. Keller;Rachel E. Woolley;Jérôme Le Nours

  • Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells

    Saar Gill;Adrianne E. Vasey;Alysha De Souza;Jeanette Baker

  • Immunosurveillance and therapy of multiple myeloma are CD226 dependent

    Camille Guillerey;Camille Guillerey;Lucas Ferrari de Andrade;Lucas Ferrari de Andrade;Slavica Vuckovic;Kim Miles

  • A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma.

    Chanyoon Cheah;Kirsten Herbert;Kacey M O'Rourke;Glen A Kennedy

  • Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network

    C. Y. Cheah;C. Y. Cheah;A. George;E. Gine;A. Chiappella

  • Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen

    S Peinert;H M Prince;H M Prince;P M Guru;M H Kershaw

  • Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance.

    Robert Weinkove;Robert Weinkove;Zoe K McQuilten;Jonathan Adler;Meera R Agar

  • CAR-T cells inflict sequential killing of multiple tumor target cells

    Alexander J Davenport;Alexander J Davenport;Misty R Jenkins;Ryan Stanley Cross;Carmen S. Yong

  • A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia

    Simon Z He;Samantha Busfield;David S Ritchie;Mark S Hertzberg

  • Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy.

    D A Carney;D A Westerman;D A Westerman;C S Tam;A Milner

  • The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial

    Constantine Tam;Constantine Tam;Andrew P Grigg;Stephen Opat;Matthew Ku

Frequent Co-Authors

John F. Seymour
John F. Seymour Peter MacCallum Cancer Centre
Jeff Szer
Jeff Szer Peter MacCallum Cancer Centre
Constantine S. Tam
Constantine S. Tam University of Melbourne
H. Miles Prince
H. Miles Prince Peter MacCallum Cancer Centre
Andrew Grigg
Andrew Grigg Austin Hospital
Andrew W. Roberts
Andrew W. Roberts Walter and Eliza Hall Institute of Medical Research
Mark J. Smyth
Mark J. Smyth QIMR Berghofer Medical Research Institute
Monica A. Slavin
Monica A. Slavin Peter MacCallum Cancer Centre
Joseph A. Trapani
Joseph A. Trapani Peter MacCallum Cancer Centre
Phillip K. Darcy
Phillip K. Darcy Peter MacCallum Cancer Centre

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in immunology opens doors to various healthcare professions that often require specialized education. For those interested in nursing, exploring lpn programs easy to get into can be a great starting point. These programs provide foundational clinical skills and can lead to further advancement in the medical field.

Many students opt for flexibility through online education, making easiest online nurse practitioner programs a popular choice. These programs allow for convenient study schedules while preparing students for advanced practice roles.

For those interested in mental health, specializing as a psychiatric mental health nurse practitioner is highly rewarding. Finding the best online psychiatric mental health nurse practitioner programs is key to gaining quality clinical experience and maximizing career opportunities.

Cost is also an important consideration. Prospective students should review options like affordable pmhnp programs to balance financial investment with educational quality.

Overall, these pathways provide valuable routes for those passionate about immunology and healthcare, combining practical skills with specialized knowledge to contribute effectively in diverse medical settings.

Best Scientists Citing David Ritchie

Trending Scientists